Related Experiment Video

Updated: Apr 28, 2026

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

24.0K

miR-124 exhibits antiproliferative and antiaggressive effects on prostate cancer cells through PACE4 pathway

Shaosan Kang1, Yansheng Zhao, Kaimeng Hu

  • 1Department of Urinary Surgery, Hebei United University Affiliated Hospital, Tangshan, Hebei, China.

The Prostate
|June 11, 2014
PubMed
Abstract

Insights

This study identifies miR-124 as a key microRNA that targets PACE4, significantly reducing prostate cancer (PCa) malignancy and invasiveness. This finding offers a potential therapeutic strategy for controlling PCa progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • PACE4 is implicated in prostate cancer (PCa) proliferation and aggression.
  • Targeting PACE4 presents a potential therapeutic strategy for PCa.
  • Identifying key microRNAs (miRNAs) can help reduce PCa malignancy and invasiveness by regulating PACE4.

Purpose of the Study:

  • To identify specific miRNAs that regulate PACE4 expression.
  • To investigate the role of these miRNAs in decreasing PCa malignancy and invasiveness.
  • To explore potential therapeutic targets for prostate cancer.

Main Methods:

  • Clinically pathological analysis (immunohistochemistry/in situ hybridization) to correlate PACE4/miRNA expression with PCa malignancy.
  • In vitro studies using prostate cell lines (DU145, C4-2, BPH-1) to assess cell growth, invasion, and PACE4 signaling.
  • Bioinformatic prediction, real-time PCR, luciferase reporter assays, and miRNA mimic/inhibitor transfections to validate miRNA targeting of PACE4.

Main Results:

  • PACE4 expression levels correlate with the pathological malignancy and invasiveness of prostate lesions.
  • DU145 cells, exhibiting high PACE4 expression, demonstrated the strongest malignancy and invasiveness.
  • miR-124 was identified as a potent inhibitor of PACE4, significantly reducing cell growth and invasion by targeting PACE4-3'UTR.

Conclusions:

  • PACE4 levels are closely associated with PCa malignancy and invasiveness.
  • miR-124 plays a critical role in inhibiting PACE4 transcription.
  • miR-124 demonstrates significant anti-proliferative and anti-aggressive effects on prostate cancer cells.
Keywords:
furininvasivenessmalignancytumor progress

More Related Videos

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

9.3K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.3K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K